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Type 2 DiabeTeS MelliTuS: RiSk evaluaTion 
anD aDvice in unDeRgRaDuaTe STuDenTS in 
aShRafieh, lebanon
F. Fneish
Hochschule Hannover, Hannover, Germany
Background: Type 2 diabetes mellitus (T2DM) is a chronic lifestyle 
disease. It has become evident that T2DM occurs even among the 
younger age groups.1 In Lebanon, T2DM has a major public health 
impact through high disease prevalence, significant downstream 
pathophysiologic effects, and enormous financial liabilities.2
Objectives: The aim of this study was to determine the risk of T2DM 
among undergraduate students from Ashrafieh city by using the vali-
dated Diabetes Risk Score Questionnaire. This study also offered 
T2DM education and awareness to respondents.
Methods: A cross-sectional study was conducted by using a validated 
questionnaire. Of the total 100 students approached, 79 accepted to par-
ticipate in the study. Respondents were interviewed and scored by using 
the Diabetes Risk Score Questionnaire on the basis of 4 parameters: 
age, abdominal obesity, physical activity, and family history of diabetes.
Results: : Of 79 students screened by using the Diabetes Risk Score 
Questionnaire, 39 (49%) were male, and 40 (51%) were female. In 
description, 23 (29%) respondents were not doing any exercise, and 
only 40 (51%) respondents were without abdominal obesity. Overall, 
10%, 44%, and 46% of the respondents were found to be in the high, 
moderate, and low diabetes risk groups, respectively.
Conclusions: According to the International Diabetes Federation, the 
projected prevalence of T2DM among adults in Lebanon for 2020 is 
20.4%. Our study found that only 46% of respondents were in the low-
risk category. Thus, it is essential to enhance awareness among the youth 
regarding T2DM and also of obesity and physical activity, as most of the 
respondents were found to lead a sedentary lifestyle. Therefore, as per 
the study plan at the end of the questionnaire, a booklet on “Diabetes 
Prevention Advice” was provided to all the respondents.
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coMpulSoRy licenSe in The eu—Two SiDeS 
of The SaMe coin
T. Baranek
LaNova Consulting s.r.o, Jachymov, Czech Republic
A compulsory license state-order is limiting the effects of an indus-
trial property right. To obtain a compulsory license, a licensee must 
first have tried unsuccessfully to obtain the property right of a license 
from the owner. Furthermore, this property right has to be in effect 
and in place. The licensee must have the ability and the willingness 
to use the intellectual property right for his own account. Thus, 
a compulsory license cannot be assigned to third parties. If these 
aforementioned conditions are met, there are 2 conditions for grant-
ing a compulsory license: (1) the licensee has a licensing related to 
the dependent property rights, which is an essential advancement of 
the patented technology; or (2) there is a public interest in granting 
a compulsory license, which is much more common in the case of 
pharmaceutical patents. Normally, public interest is defined that a 
medical treatment method or a drug (in the legal sense) should be 
accessible for each person in principle. This accessibility is not been 
given if a treatment method or a drug is only offered subjectively 
too expensive. Rather, a particularly high benefit must be claimed; 
e.g. initial treatment option of common diseases with good pros-
pects of efficacy, e.g. the domestic market is insufficient supplied or 
if the drug or the investigational medicinal product has much less 
side effects so far. Public interest is, in this case not stated, if the 
treatment results can be achieved with other, more or less equiva-
lent, alternatives. For example, the European Union (EU) published 
on May 17, 2006, a Regulation (EC Regulation No. 816/2006) 
on compulsory licensing of patents relating to the manufacture of 
pharmaceutical products for export to countries with public health 
problems. This regulation establishes a procedure for companies 
in the EU wishing to manufacture generic medicines for use in the 
developing world to apply for a compulsory license from a patent 
holder, which allows their manufacture. The legislation is part of 
wider EU action to tackle public health concerns that the world’s 
least developed and developing countries face, in particular access 
to safe, effective, and affordable medicines. This article compares 
arguments of both opponents and proponents of compulsory licens-
ing, which is a legitimate safeguard provided under the EU and in 
the same line as the TRIPS (Agreement on Trade-Related Aspects 
of Intellectual Property Rights by the World Trade Organization) 
to check misuse of monopoly and to deal with situations of public 
health crisis, especially in the Third World.
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Background: The lives of far too many in the world are being 
blighted and cut short by age- and lifestyle-related chronic diseases 
such as heart disease, stroke, cancer, chronic respiratory diseases, and 
diabetes resulting from urbanization, sedentary lifestyles, changing 
diets, and rising obesity levels. 1Even problems of child overweight 
and obesity are increasing worldwide, leading to a growing inci-
dence of type 2 diabetes. India is the second most populated country 
with a population of > 1.2 billion. Along with this, India’s working 
population is also increasing, which will help the Indian economy 
to grow at a much faster rate than the other emerging economies. 
The working population in India is expected to be close to 64% in 
2026. However, with the increase in the young working population 
and change in lifestyle of this young population, there has been an 
increase in lifestyle-related diseases. The current generation, which 
is used to deskbound work, alcohol consumption, and smoking, 
is more prone to such lifestyle-related diseases.2 It is of great con-
cern to observe elevations in the key risk factors that contribute to 
chronic diseases: use of alcohol/tobacco, obesity, and environmental 
S6 Abstract
pollution. At the same time, underdiagnosis and the large number 
of cases of cancers not being detected makes the situation more 
alarming.3,4
Methods: A detailed search was conducted from national5 and 
international6 databases related to chronic disease care in India and 
globally to identify publicly released reports relevant to chronic dis-
eases such as diabetes, cancer, and cardiovascular disease, with more 
emphasis and focus on diabetes and cancer.
Results: The prevalence of diabetes has increased 10-fold between 
1971 and 2000.6 It is expected to increase to 101.2 million by 2030,7 
and 77.2 million people in India are said to have prediabetes.8 More 
than 20% of the population in India have at least 1 chronic disease 
and > 10% have > 1 chronic disease.9 According to the World Health 
Organization, if 1 adult in a low-income family has diabetes, as much 
as 25% of family income may be devoted to diabetes care.10 In an 
industrialized country such as Germany, due to lifestyle changes, it 
is expected that there will be a > 20% increase in new cases of cancer 
between 2010 and 2030.11 Awareness level, knowledge of disease 
symptoms, and screening practices were the key attributes evaluated 
in a study of breast cancer.3 It was observed among the participants 
that 56% had not heard of and 65% were not practicing breast 
self-examination. According to Ernst and Young, baseline cost of 
treatment (estimated Indian Rupees 300,000–400,000 lakhs) being 
higher than the annual house hold income for > 80% to 85% of 
households in India, cancer poses a significant threat to the Indian 
population.3 With the launch of sodium glucose co-transporter 2 
inhibitors and teneligliptin, oral drugs have taken diabetes care to the 
next level, which has shown improved glycemic control and reduc-
tion in glycosylated hemoglobin.12,13 Key risk factors (eg, alcohol per 
capita consumption in adults aged > 15 years) has increased by 55% 
between 1992 and 2012.3 Prevalence of all forms of tobacco use in 
India in 2015 was 17%, and it is one of the key factors associated 
with the increased risk of head and neck, lung, and bladder cancers.
Conclusions: Despite the steep increase expected in chronic diseases, 
India’s health care professional and infrastructure shortage is one of 
the major reasons for the country’s high mortality rate. However, the 
public sector’s lackadaisical performance due to limited investments 
and suboptimal utilization of available resources has hampered the 
growth of health care facilities. The growing burden of noncommuni-
cable diseases (NCDs)/communicable diseases is the leading cause of 
death pertaining to the ageing population, high calorie consumption, 
and low physical activity levels, accounting for 60% of all deaths in 
India. In addition, NCDs/communicable diseases account for ~40% 
of hospital stays and nearly 35% of all recorded outpatient depart-
ment visits. An ageing population and changes in societal behavior 
are contributing to a steady increase in these common and costly 
long-term health problems. The middle class is growing, and with 
urbanization accelerating, people are adopting a more sedentary 
lifestyle. This is pushing obesity rates and cases of diseases such as 
diabetes upward. The government’s low spending on health care 
places much of the burden on patients and their families, however, 
as evidenced by the country’s out-of-pocket spending rate, one of the 
world’s highest. Although the government has taken significant meas-
ures to improve access to quality care, it has also seen the emergence 
of innovative delivery models by private players to address growing 
chronic care demands. Technology (telemedicine) has a key role to 
play. Advancements in precise detection and diagnosis of disease 
will go far to minimize the cost of treating chronic conditions. The 
economic burden is further diminished due to poor health, as the 
probability of dying due to chronic diseases is 26% among the most 
productive years (ie, the 30- to 70-year-old age group). It is estimated 
that the increasing NCD burden is expected to lead to as much as US$ 
4.58 trillion loss of output between 2012 and 2030. Cardiovascular 
diseases are the major contributors (48%) to the economic burden.
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auDiTing TRipS iMpacT on acceSS vS. 
Monopoly on public healTh
V.C. Vivekanandan
NALSAR University of Law, Shameerpet, India
Two decades of the TRIPS (Trade Related Intellectual Properties) 
agreement aimed at strengthening the “monopoly” rights of innova-
tors and creators has brought in visible gains for the investors bank-
ing on intellectual property rights for trade and commerce across 
the nation states. However, such an agreement and implementation 
spree has been reluctant to answer the question of access to medi-
cines to vast majority of the population, including that of the devel-
oped countries. Although adherence to the standards of TRIPS and 
up- gradation to ‘TRIPS Plus” has been the central focus of various 
bilateral and multilateral talks for investment and trade among trad-
ing blocks, the issue of “access” finds a muted response. A decade 
ago in the year 2007, the World Intellectual Property Organization 
(WIPO) adapted the WIPO development agenda endorsed by the 
member states, which led to the adoption of “45 Development 
Agenda Recommendations” and thereupon the establishment of the 
Committee on Development and Intellectual Property,1 which reig-
nited the hope of shaping the intellectual property agenda to balance 
“access versus monopoly.” However, in the intervening decade, the 
rise of the Anti-Counterfeiting Trade Agreement, the Trans-Pacific 
